Four-year data show preservation of cardiac function, including LVEFSkeletal muscle disease progression continues to slow ...

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s ...

Capricor Therapeutics (NASDAQ:CAPR) received the Orphan Drug designation from the U.S. FDA for its lead cell therapy ...

Capricor Therapeutics' rating was downgraded amid FDA inspection risks, regulatory uncertainty, and potential delays in ...

Capricor Therapeutics (NASDAQ:CAPR) shares dropped after the U.S. FDA inspected its San Diego manufacturing facility for the ...

Benzinga's options scanner spotted 10 options trades for Capricor Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 20% bullish and 70% bearish. Among ...

Capricor Therapeutics has received an orphan drug designation for its drug aimed at potentially treating Becker Muscular Dystrophy. The biotechnology company said Tuesday that the Food and Drug ...

24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases ...

Capricor Therapeutics has announced the appointment of Dr. Michael Binks as Chief Medical Officer, effective immediately. Dr. Binks brings 25 years of experience in clinical development and ...

For more information, or to register, please click here. Capricor plans to make its presentation available on the publications section of the Company’s website following the formal conference ...

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseases Capricor remains on track for the ...